There are no absolute contraindications listed for inotuzumab ozogamicin, but it should be used with caution in certain situations. Patients with a history of severe liver disease, including previous veno-occlusive disease (VOD) or ongoing serious liver problems, may be at increased risk for severe side effects and should discuss these risks with their doctor.

Women who are pregnant should not take inotuzumab ozogamicin, as it can cause harm to an unborn baby. Women should use effective contraception during treatment and for 8 months after the last dose. Men with female partners of reproductive potential should use contraception during treatment and for 5 months after the last dose. Breastfeeding is not recommended during treatment and for 2 months after the last dose.

inotuzumab ozogamicin

Common brand names

Approved use in